Spojené štáty - angličtina - NLM (National Library of Medicine)

stat rx usa llc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1.   pharyngitis/tonsillitis caused by streptococcus pyogenes.      note : the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. th

Spojené štáty - angličtina - NLM (National Library of Medicine)

medvantx, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology) cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:  1. pharyngitis/tonsillitis caused by streptococcus pyogenes. note: the usual dr

Spojené štáty - angličtina - NLM (National Library of Medicine)

a-s medication solutions - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacte

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime;   - powder for injection - 1.5 g - active: cefuroxime sodium 1578mg equivalent to 1500 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 263mg equivalent to 250 mg cefuroxime;   - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to 250 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

Spojené štáty - angličtina - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - tablet - 125 mg - note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. pharyngitis/tonsillitis caused by streptococcus pyogenes. note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. there are

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

viatris limited - cefuroxime sodium 263mg equivalent 250 mg cefuroxime - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent 250 mg cefuroxime

Spojené štáty - angličtina - NLM (National Library of Medicine)

sagent pharmaceuticals - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - men

Spojené štáty - angličtina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae , haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin­-structure infections caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pyogenes , escherichia coli , klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), streptococcus pneumoniae , escherichia coli , haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - mening